{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:49:14Z","timestamp":1789526954182,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["127779"],"award-info":[{"award-number":["127779"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001321","name":"National Research Foundation","doi-asserted-by":"publisher","award":["SRUG2204305498"],"award-info":[{"award-number":["SRUG2204305498"]}],"id":[{"id":"10.13039\/501100001321","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Onderstepoort Biological Products","award":["RDV19-002"],"award-info":[{"award-number":["RDV19-002"]}]},{"name":"Onderstepoort Biological Products","award":["RDV19-002"],"award-info":[{"award-number":["RDV19-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The live-attenuated Rift Valley Fever Smithburn (SB) vaccine is one of the oldest products widely used in ruminants for control of RVF infections. Vaccinations with RVF Smithburn result in residual pathogenic effect and is limited for use in non-pregnant animals. Commercially available RVFV inactivated vaccines are considered safer options to control the disease. These products are prepared from virulent RVFV isolates and present occupational safety concerns. This research study evaluates the ability of an inactivated SB vaccine strain to elicit neutralising antibody response in sheep.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The RVF Smithburn vaccine was inactivated with binary ethylenimine at 37\u00a0\u00b0C. Inactivated RVFV cultures were adjuvanted with Montande\u2122 Gel-01 and aluminium hydroxide (Al (OH)<jats:sub>3<\/jats:sub>) gel for immunogenicity and safety determination in sheep. The commercial RVF inactivated vaccine and a placebo were included as positive and negative control groups, respectively.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Inactivated RVFV vaccine formulations were safe with all animals showing no clinical signs of RVFV infection and temperature reactions following prime-boost injections. The aluminium hydroxide formulated vaccine induced an immune response as early as 14 days post primary vaccination with neutralising antibody titre of 1:20 and a peak antibody titre of 1:83 was reached on day 56. A similar trend was observed in the animal group vaccinated with the commercial inactivated RVF vaccine obtaining the highest antibody titre of 1:128 on day 56. The neutralizing antibody levels remained within a threshold for the duration of the study. Merino sheep vaccinated with Montanide\u2122 Gel-01-Smithburn were characterised with overall lower immune response when compared to aluminium hydroxide vaccine emulsions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These finding suggests that the inactivated RVF Smithburn vaccine strain adjuvanted with aluminium-hydroxide can be used an alternative to the products prepared from virulent RVFV isolates for protection of ruminants against the disease. The vaccine can further be evaluated for safety in pregnant ewes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12985-023-02180-2","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:02:11Z","timestamp":1696338131000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Safety and immunogenicity of inactivated Rift Valley Fever Smithburn viral vaccine in sheep"],"prefix":"10.1186","volume":"20","author":[{"given":"Matome Selina","family":"Matsiela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeann","family":"Naicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thandeka","family":"Khoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobalanda","family":"Mokoena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"issue":"7","key":"2180_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2460\/javma.234.7.883","volume":"234","author":"BH Bird","year":"2009","unstructured":"Bird BH, et al. Rift Valley fever virus. J Am Vet Med Assoc. 2009;234(7):883\u201393.","journal-title":"J Am Vet Med Assoc"},{"issue":"8","key":"2180_CR2","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2174\/156652405774962263","volume":"5","author":"R Flick","year":"2005","unstructured":"Flick R, Bouloy M. Rift Valley fever virus. Curr Mol Med. 2005;5(8):827\u201334.","journal-title":"Curr Mol Med"},{"key":"2180_CR3","volume-title":"Infectious diseases of livestock","author":"R Swanepoel","year":"2004","unstructured":"Swanepoel R. Rift Valley fever. In: Coetzer JAW, Tustin RC, editors. Infectious diseases of livestock. Cape Town: Oxford University Press; 2004."},{"issue":"6","key":"2180_CR4","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1080\/14760584.2017.1321482","volume":"16","author":"T Ikegami","year":"2017","unstructured":"Ikegami T. Rift Valley fever vaccines: an overview of the safety and efficacy of the live-attenuated MP-12 vaccine candidate. Expert Rev Vaccines. 2017;16(6):601\u201311.","journal-title":"Expert Rev Vaccines"},{"issue":"4","key":"2180_CR5","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/path.1700340418","volume":"34","author":"R Daubney","year":"1931","unstructured":"Daubney R, Hudson J, Garnham P. Enzootic hepatitis or Rift Valley fever. An undescribed virus disease of sheep cattle and man from East Africa. J Pathol Bacteriol. 1931;34(4):545\u201379.","journal-title":"J Pathol Bacteriol"},{"issue":"6","key":"2180_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1051\/vetres\/2010033","volume":"41","author":"M Pepin","year":"2010","unstructured":"Pepin M, et al. Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention. Vet Res. 2010;41(6):61.","journal-title":"Vet Res"},{"issue":"2","key":"2180_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/tropicalmed5020089","volume":"5","author":"EN Grossi-Soyster","year":"2020","unstructured":"Grossi-Soyster EN, LaBeaud AD. Rift Valley fever: important considerations for risk mitigation and future outbreaks. Trop Med Infect Dis. 2020;5(2):89.","journal-title":"Trop Med Infect Dis"},{"issue":"3","key":"2180_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/vaccines5030029","volume":"5","author":"B Faburay","year":"2017","unstructured":"Faburay B, et al. Current status of Rift Valley fever vaccine development. Vaccines. 2017;5(3):29.","journal-title":"Vaccines"},{"issue":"6","key":"2180_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nbt.1635","volume":"28","author":"AS Lauring","year":"2010","unstructured":"Lauring AS, Jones JO, Andino R. Rationalizing the development of live-attenuated virus vaccines. Nat Biotechnol. 2010;28(6):573\u20139.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2180_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","volume":"9","author":"J Morrill","year":"1991","unstructured":"Morrill J, et al. Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep. Vaccine. 1991;9(1):35\u201341.","journal-title":"Vaccine"},{"issue":"6","key":"2180_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1002\/jmv.20624","volume":"78","author":"B Botros","year":"2006","unstructured":"Botros B, et al. Adverse response of non-indigenous cattle of European breeds to live-attenuated Smithburn Rift Valley fever vaccine. J Med Virol. 2006;78(6):787\u201391.","journal-title":"J Med Virol"},{"issue":"1","key":"2180_CR12","first-page":"1","volume":"30","author":"K Smithburn","year":"1949","unstructured":"Smithburn K. Rift Valley fever: the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol. 1949;30(1):1.","journal-title":"Br J Exp Pathol"},{"key":"2180_CR13","first-page":"100070","volume":"6","author":"Z Boumart","year":"2020","unstructured":"Boumart Z, et al. Safety and immunogenicity of the Rift Valley fever arMP-12 \u0394NSm21\/384 candidate vaccine in pregnant ewes. Vaccine: X. 2020;6:100070.","journal-title":"Vaccine: X"},{"issue":"1","key":"2180_CR14","doi-asserted-by":"publisher","first-page":"e0007898","DOI":"10.1371\/journal.pntd.0007898","volume":"14","author":"J Oymans","year":"2020","unstructured":"Oymans J, et al. Rift Valley fever virus targets the maternal-foetal interface in ovine and human placentas. PLoS Negl Trop Dis. 2020;14(1):e0007898.","journal-title":"PLoS Negl Trop Dis"},{"key":"2180_CR15","first-page":"100060","volume":"5","author":"TP Monath","year":"2020","unstructured":"Monath TP, et al. Theoretical risk of genetic reassortment should not impede development of live, attenuated Rift Valley fever (RVF) vaccines commentary on the draft WHO RVF Target Product Profile. Vaccine: X. 2020;5:100060.","journal-title":"Vaccine: X"},{"key":"2180_CR16","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.3201\/eid1712.111035","volume":"17","author":"AA Grobbelaar","year":"2011","unstructured":"Grobbelaar AA, et al. Molecular epidemiology of Rift Valley fever virus. Emerg Infect Dis. 2011;17:2270.","journal-title":"Emerg Infect Dis"},{"key":"2180_CR17","first-page":"7346294","volume":"2016","author":"M Alhaj","year":"2016","unstructured":"Alhaj M. Safety and efficacy profile of commercial veterinary vaccines against Rift Valley fever: a review study. J Immunol Re. 2016;2016:7346294.","journal-title":"J Immunol Re"},{"key":"2180_CR18","first-page":"100209","volume":"12","author":"MS Matsiela","year":"2022","unstructured":"Matsiela MS, et al. Improved safety profile of inactivated Neethling strain of the lumpy skin disease vaccine. Vaccine: X. 2022;12:100209.","journal-title":"Vaccine: X"},{"issue":"8","key":"2180_CR19","doi-asserted-by":"publisher","first-page":"e002694","DOI":"10.1136\/bmjgh-2020-002694","volume":"5","author":"V Petrova","year":"2020","unstructured":"Petrova V, et al. Rift valley fever: diagnostic challenges and investment needs for vaccine development. BMJ Glob Health. 2020;5(8):e002694.","journal-title":"BMJ Glob Health"},{"key":"2180_CR20","doi-asserted-by":"publisher","first-page":"7346294","DOI":"10.1155\/2016\/7346294","volume":"2016","author":"M Alhaj","year":"2016","unstructured":"Alhaj M. Safety and efficacy profile of commercial veterinary vaccines against Rift Valley Fever: a review study. J Immunol Res. 2016;2016:7346294.","journal-title":"J Immunol Res"},{"key":"2180_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.coviro.2018.02.001","volume":"29","author":"B Dungu","year":"2018","unstructured":"Dungu B, Lubisi BA, Ikegami T. Rift Valley fever vaccines: current and future needs. Curr Opin Virol. 2018;29:8\u201315.","journal-title":"Curr Opin Virol"},{"issue":"1","key":"2180_CR22","first-page":"45","volume":"48","author":"B Barnard","year":"1977","unstructured":"Barnard B, Botha M. An inactivated rift valley fever vaccine. J S Afr Vet Assoc. 1977;48(1):45\u20138.","journal-title":"J S Afr Vet Assoc"},{"issue":"3","key":"2180_CR23","doi-asserted-by":"publisher","first-page":"e06041","DOI":"10.2903\/j.efsa.2020.6041","volume":"18","author":"SS Nielsen","year":"2020","unstructured":"Nielsen SS, et al. Rift Valley Fever\u2013epidemiological update and risk of introduction into Europe. EFSA J. 2020;18(3):e06041.","journal-title":"EFSA J"},{"issue":"2","key":"2180_CR24","doi-asserted-by":"publisher","first-page":"86","DOI":"10.4161\/bact.1.2.15456","volume":"1","author":"B Anderson","year":"2011","unstructured":"Anderson B, et al. Enumeration of bacteriophage particles: comparative analysis of the traditional plaque assay and real-time QPCR-and nanosight-based assays. Bacteriophage. 2011;1(2):86\u201393.","journal-title":"Bacteriophage"},{"issue":"1","key":"2180_CR25","first-page":"47","volume":"47","author":"H Bahnemann","year":"1975","unstructured":"Bahnemann H. Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Adv Virol. 1975;47(1):47\u201356.","journal-title":"Adv Virol"},{"issue":"3","key":"2180_CR26","doi-asserted-by":"publisher","first-page":"000191","DOI":"10.1099\/acmi.0.000191","volume":"3","author":"B Moetlhoa","year":"2021","unstructured":"Moetlhoa B, et al. Application of a real-time cell analysis system in the process development and quantification of Rift Valley fever virus clone 13. Access Microbiol. 2021;3(3):000191.","journal-title":"Access Microbiol"},{"issue":"1","key":"2180_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4102\/ojvr.v81i1.675","volume":"81","author":"CE Ellis","year":"2014","unstructured":"Ellis CE, et al. Validation of an ELISA for the concurrent detection of total antibodies (IgM and IgG) to Rift Valley fever virus. Onderstepoort J Vet Res. 2014;81(1):1\u20136.","journal-title":"Onderstepoort J Vet Res"},{"issue":"1","key":"2180_CR28","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1439-0450.1971.tb00343.x","volume":"18","author":"HR Frey","year":"1971","unstructured":"Frey HR, Liess B. Vermehrungskinetik und Verwendbarkeit eines stark zytopathogenen VD-MD-Virusstammes f\u00fcr diagnostische Untersuchungen mit der Mikrotiter-Methode. Zentralbl Veterinarmed B. 1971;18(1):61\u201371.","journal-title":"Zentralbl Veterinarmed B"},{"key":"2180_CR29","first-page":"493","volume":"27","author":"HR Muench","year":"1938","unstructured":"Muench HR. A simple method of estimating 50 per cent end points. Am J Hyg. 1938;27:493\u20137.","journal-title":"Am J Hyg"},{"issue":"5","key":"2180_CR30","doi-asserted-by":"publisher","first-page":"e0006474","DOI":"10.1371\/journal.pntd.0006474","volume":"12","author":"DR Smith","year":"2018","unstructured":"Smith DR, et al. Attenuation and efficacy of live-attenuated Rift Valley fever virus vaccine candidates in non-human primates. PLoS Negl Trop Dis. 2018;12(5):e0006474.","journal-title":"PLoS Negl Trop Dis"},{"key":"2180_CR31","doi-asserted-by":"crossref","unstructured":"Al-Olayan EM et al (2016) An alternative inactivant for Rift Valley Fever virus using cobra venom-derived L-amino oxidase, which is related to its immune potential. Braz Arch Biol Technol 59","DOI":"10.1590\/1678-4324-2016160044"},{"issue":"3","key":"2180_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/0166-0934(91)90036-Y","volume":"33","author":"N Blackburn","year":"1991","unstructured":"Blackburn N, Besselaar T. A study of the effect of chemical inactivants on the epitopes of Rift Valley fever virus glycoproteins using monoclonal antibodies. J Virol Methods. 1991;33(3):367\u201374.","journal-title":"J Virol Methods"},{"issue":"1","key":"2180_CR33","first-page":"239","volume":"27","author":"DMA Magd","year":"2014","unstructured":"Magd DMA, et al. Effecacy of Montanide gel inactivated RVF vaccine in comparison with aluminum hydroxide gel inactivated one. Benha Vet Med J. 2014;27(1):239\u201347.","journal-title":"Benha Vet Med J"},{"issue":"1\u20132","key":"2180_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.vetmic.2006.11.008","volume":"121","author":"JM Fafetine","year":"2007","unstructured":"Fafetine JM, et al. Cloning and expression of Rift Valley fever virus nucleocapsid (N) protein and evaluation of a N protein based indirect ELISA for the detection of specific IgG and IgM antibodies in domestic ruminants. Vet Microbiol. 2007;121(1\u20132):29\u201338.","journal-title":"Vet Microbiol"},{"key":"2180_CR35","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fvets.2020.00256","volume":"7","author":"DB Wallace","year":"2020","unstructured":"Wallace DB, et al. Protection of cattle elicited using a bivalent lumpy skin disease virus-vectored recombinant Rift Valley fever vaccine. Front Vet Sci. 2020;7:256.","journal-title":"Front Vet Sci"},{"key":"2180_CR36","doi-asserted-by":"publisher","first-page":"106498","DOI":"10.1016\/j.actatropica.2022.106498","volume":"232","author":"GF Ronchi","year":"2022","unstructured":"Ronchi GF, et al. Immunogenicity and safety studies of an inactivated vaccine against Rift Valley fever. Acta Trop. 2022;232:106498.","journal-title":"Acta Trop"},{"key":"2180_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s00430-016-0457-y","volume":"205","author":"E Corrales-Aguilar","year":"2016","unstructured":"Corrales-Aguilar E, et al. Highly individual patterns of virus-immune IgG effector responses in humans. Med Microbiol Immunol. 2016;205:409\u201324.","journal-title":"Med Microbiol Immunol"},{"issue":"2","key":"2180_CR38","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.4049\/jimmunol.0902147","volume":"186","author":"K El Bakkouri","year":"2011","unstructured":"El Bakkouri K, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol. 2011;186(2):1022\u201331.","journal-title":"J Immunol"},{"issue":"9","key":"2180_CR39","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.4049\/jimmunol.172.9.5598","volume":"172","author":"A Jegerlehner","year":"2004","unstructured":"Jegerlehner A, et al. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004;172(9):5598\u2013605.","journal-title":"J Immunol"},{"issue":"6","key":"2180_CR40","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.4049\/jimmunol.181.6.4168","volume":"181","author":"DM Carragher","year":"2008","unstructured":"Carragher DM, et al. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol. 2008;181(6):4168\u201376.","journal-title":"J Immunol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02180-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-023-02180-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-023-02180-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T00:27:52Z","timestamp":1700353672000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-023-02180-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2180"],"URL":"https:\/\/doi.org\/10.1186\/s12985-023-02180-2","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,3]]},"assertion":[{"value":"15 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The veterinary clinical trial experiment was performed according to the approved protocol by the OBP Animal Ethics Committee (South African Veterinary Council Facility Registration Number: FR1514054) under approval number OBP2019\/002 and Department of Agriculture, Land Reform and Rural Development under section 20 of Animal Diseases Act (Act 35 of 1984); approval number 12\/11\/1\/1\/(b) MG. The animals included in the study were cleared by the state veterinarian to be free from any communicable diseases affecting ovine. The Langfontein farm where animals are sourced was not under any quarantine at the time of sourcing the sheep as per section 20 of Act 35 of 1984.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare the following financial interests which may be considered as potential competing interests: The project was also funded internally from Onderstepoort Biological Products Research budget.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}